The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
Abstract
The liver is critical to consider during drug development because of its central role in the handling of xenobiotics, a process which often leads to localized and/or downstream tissue injury. Our ability to predict human clinical safety outcomes with animal testing is limited due to species differences in drug metabolism and disposition, while traditional human in vitro liver models often lack the necessary in vivo physiological fidelity. To address this, increasing numbers of liver microphysiological systems (MPS) are being developed, however the inconsistency in their optimization and characterization often leads to models that do not possess critical levels of baseline performance that is required for many pharmaceutical industry applications. Herein we provide a guidance on best approaches to benchmark liver MPS based on 3 stages of characterization that includes key performance metrics and a 20 compound safety test set. Additionally, we give an overview of frequently used liver injury safety assays, describe the ideal MPS model, and provide a perspective on currently best suited MPS contexts of use. This pharmaceutical industry guidance has been written to help MPS developers and end users identify what could be the most valuable models for safety risk assessment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These consortia not only promote MPS and OoC adoption but also generate lists of reference compounds relevant to various organ systems (Ainslie et al., 2019; Baudy et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Phillips et al., 2020; Pointon et al., 2021).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Baudy et al., 2020
In the citing paper
“Guided by the IQ MPS affiliate’s roadmap on liver MPS19, which states that in vitro models for predicting drug-induced liver injury (DILI) that meet its guidelines are more likely to exhibit higher predictive validity than those that do not”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
In the citing paper
“Albumin and urea production are widely accepted as functional markers for cultured hepatocytes with the goal of reaching computed production levels observed in human liver in vivo (~20–105 µg and 56–159 µg per 106 hepatocytes per day, respectively)19,26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Heroux, J., & Gharib, A. M. (2008) · Molecular Imaging in Oncology · doi:10.3109/9781420019957-3 · Cited by 2,187
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
Barst, R. J., Langleben, D., Frost, A., Horn, E. M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V. F., Robbins, I. M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-957oc · Cited by 706
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Research works printed but not linked: 15
- R. Becker , A.Chakravarty , D.Cho , O.Faris , S.Fitzpatrick , N.Hunter , I.Irony , S.Lababidi , C.Leptak , W.Mattes , E.Mishina , K.O'Callaghan , M.Pacanowski , E.Papadopoulos , V.Peiris , R.Puri , M.Robb , H.Rogers , R.Sherman , R.Sridhara , R.Temple , A.Trentacosti , P.Turfle , S.Wang , H.Hamilton , P.McInnes , L.McShane and M.Shah , BEST (Biomarkers, EndpointS, and other Tools) Resource , Silver Spring (MD) , 2018
- Kizawa, 2017, Biochem. Biophys. Rep., 10, 186
- Chen, 2013, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
- Hosey, 2016, AAPS J., 18, 251, 10.1208/s12248-015-9845-2 · DOI
- Shah, 2015, Toxicol. Sci., 147, 500, 10.1093/toxsci/kfv152 · DOI · Paper page
- Kock, 2014, Drug Metab. Dispos., 42, 665, 10.1124/dmd.113.054304 · DOI · Paper page
- Morgan, 2010, Toxicol. Sci., 118, 485, 10.1093/toxsci/kfq269 · DOI · Paper page
- Aleo, 2014, Hepatology, 60, 1015, 10.1002/hep.27206 · DOI · Paper page
- Proctor, 2017, Arch. Toxicol., 91, 2849, 10.1007/s00204-017-2002-1 · DOI · Paper page
- Bell, 2016, Sci. Rep., 6, 25187, 10.1038/srep25187 · DOI · Paper page
- Ballmer, 1990, Am. J. Physiol., 259, E797
- Hovens, 1994, Ned. Tijdschr. Geneeskd., 138, 363
- Prior, 2003, J. Psychiatry Neurosci., 28, 99
- Kostrubsky, 2000, Drug Metab. Dispos., 28, 1192
- Stork, 1997, J. Toxicol., 35, 105
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Self-citation3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Wang, H., Brown, P. C., Chow, E. C. Y., Ewart, L., Ferguson, S. S., Fitzpatrick, S., Freedman, B. S., Guo, G. L., Hedrich, W., Heyward, S., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13066 · Cited by 212
“, metabolic clearance, RNA isolations, and lower sensitivity protein secretion assays), and (3) the ability to clearly image cell morphology using conventional laboratory systems.”
BackgroundSelf-citation
Metadata
- Authors
- Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Springhouse (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Bristol-Myers Squibb (United States) (US)
- F. Hoffmann-La Roche AG (CH)
- Sanofi (United States) (US)
- AbbVie (United States) (US)
- AbbVie, Inc.
- Genentech (US)
- Corresponding author
- Baudy, Andreas R.
- ORCID
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 20
- Issue
- 2
- Pages
- 215-225
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- OpenAlex
- W2990102938
- Cited by
- 150
- References
- 94
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 27 · 2020: 9
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lab on a Chip (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- liver-on-a-chip, liver injury, hepatotoxicity, model characterization, model benchmarking, key performance indicators, in vitro liver models, drug metabolism, species differences in drug metabolism, drug development
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Liver, Risk Assessment, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. https://app.cochat.ai/papers/10.1039/c9lc00768g
- The paper
- Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020). Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab on a Chip. https://doi.org/10.1039/c9lc00768g
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.